(Hedgeweek) Hedge funds have made gains from bets against AstraZeneca and GlaxoSmithKline in recent weeks – but bearish managers lost more than USD600 million on FTSE 100 shorts at the end of the year, with short sellers facing continuing “unpredictable swings” in 2021.
Hedge funds profit from AstraZeneca fall, but FTSE short sellers face continued challenges in 2021
This entry was posted in Syndicated. Bookmark the permalink.
